4.5 Article

N-glycosylation reinforces interaction of immune checkpoint TIM-3 with a small molecule ligand

Journal

COMPUTATIONAL BIOLOGY AND CHEMISTRY
Volume 104, Issue -, Pages -

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.compbiolchem.2023.107852

Keywords

Cancer; Drug binding; N-glycosylation; Immune checkpoint; Molecular modeling; TIM-3

Ask authors/readers for more resources

This study investigates the influence of protein N-glycosylation on drug-protein binding and finds that N-glycosylation can further stabilize drug-protein complexes. The glycan can interact directly with the drug to consolidate drug binding and protect the stability of drug-protein interactions. The findings have important implications for understanding the impact of N-glycosylation on drug-receptor interactions.
N-glycosylation of eukaryotic proteins plays roles in protein folding, trafficking, and signal transduction. The biological influence of the process is well understood, whereas the pharmacological impact of protein Nglycosylation is not well under discerned. The role of N-glycosylation on drug binding to protein has been rarely studied. We have modeled the influence of a bi-antennary N-glycan introduced at position N78 on the immune checkpoint TIM-3 (T cell immunoglobulin domain and mucin domain-containing molecule 3) on the interaction with a selective drug antagonist. The bulky N-glycan introduced at the consensus sequence Asn-Val-Thr has no influence on drug binding when the glycan adopts an extended conformation. But in a folded conformation, the glycan can interact directly with the triazoloquinazolinone derivative so as to further stabilize the drug-TIM-3 complex. The non-fucosylated glycan at position N78 markedly consolidates the drug interaction, via an additional H-bond interaction with the & alpha;3-mannose residue. It provides a gain of empirical potential energy of interaction (& UDelta;E) of about 30 %. The presence of a more rigid fucosylated N-glycan is a little less favorable, with a gain of & UDelta;E of about 20 %. The folded N-glycan appears to protect the ligand bound to the protein cavity, with the tricyclic core of the heterocyclic molecule sandwiched between two indole rings of tryptophan residues. Similar results were obtained when using a biantennary disialyl N-glycan with a bisecting GlcNAc residue and a tetraantennary N-glycan. The molecular models illustrate the drug-stabilizing capacity of a bulky N-glycan positioned at a validated glycosylation site (N78 corresponding to N100 for the full-length protein). The modeling approach is useful to delineate further the role of the N-glycan of the immune checkpoint TIM-3 in interaction with small molecule ligands, and to guide the design of more potent compounds. The approach is transposable to other proteins to better comprehend the influence of N-glycans on drug-receptor interactions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available